<DOC>
	<DOCNO>NCT02296411</DOCNO>
	<brief_summary>The purpose study evaluate superiority glycopyrrolate bromide ( CHF 5259 pMDI ) versus placebo top QVAR® pMDI , term lung function parameter , well assess safety .</brief_summary>
	<brief_title>Efficacy LAMA Added ICS Treatment Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>History asthma ≥ 5 year diagnose 40 year old Uncontrolled asthma lowmedium dos Inhaled CorticoSteroid ( ICS ) ACQ ( Asthma Control Questionnaire ) ≥1.5 Prebronchodilator FEV1 ≥40 % &lt; 90 % predict normal value Positive reversibility test Pregnant lactate woman Diagnosis Chronic Obstructive Pulmonary Disease ( COPD ) Patients treat asthma exacerbation 4 week prior study entry Patients therapy gastroesophageal reflux disease Patients clinically significant cardiovascular condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Asthma , Anticholinergics</keyword>
</DOC>